Managing Fatigue, Anemia, and Cardiovascular Risk in Practice

This segment focuses on real-world safety considerations, particularly fatigue, anemia, and cardiovascular risk associated with belzutifan-based therapy. The speakers note that anemia is a common effect of HIF-2α inhibition and can contribute to fatigue, which may impact patient quality of life. Concerns are also raised about cardiac dysfunction observed in the trial, especially in patients with underlying cardiovascular disease. The discussion emphasizes the importance of baseline cardiac evaluation and ongoing monitoring during treatment. In real-world practice, patients may have comorbidities not fully represented in clinical trials, making toxicity management more complex. This segment highlights the need for individualized treatment approaches and careful patient selection to mitigate risks while maximizing therapeutic benefit.